Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

dc.contributor.authorAlyassin, Yasmine
dc.contributor.authorSayed, Elshaimaa G.
dc.contributor.authorMehta, Prina
dc.contributor.authorRuparelia, Ketan
dc.contributor.authorArshad, Muhammad S.
dc.contributor.authorRasekh, Manoochehr
dc.contributor.authorShepherd, Jennifer
dc.date.accessioned2025-10-29T11:29:24Z
dc.date.issued2020
dc.departmentGebze Teknik Üniversitesi
dc.description.abstractRecently, remarkable efforts have focused on research towards enhancing and delivering efficacious and advanced therapeutic agents. Even though this involves significant challenges, innovative techniques and materials have been explored to overcome these. The advantageous properties of mesoporous silica nanoparticles (MSNs), such as unique morphologies and geometries, makes then favorable for use for various drug delivery targeting purposes, particularly in cancer therapy. As we discuss here, MSNs have been utilized over the past few decades to improve the efficiency of anticancer drugs by enhancing their solubility to render them suitable for application, reducing adverse effects, and improving their anticancer cytotoxic efficiency.
dc.description.sponsorshipCouncil for At-Risk Academics (CARA)
dc.description.sponsorshipEgyptian Culture Centre
dc.description.sponsorshipEducational Bureau in London
dc.description.sponsorshipThe authors would like to thank the Council for At-Risk Academics (CARA) and the Egyptian Culture Centre and the Educational Bureau in London for supporting this work.
dc.identifier.doi10.1016/j.drudis.2020.06.006
dc.identifier.endpage1520
dc.identifier.issn1359-6446
dc.identifier.issn1878-5832
dc.identifier.issue8
dc.identifier.orcid0000-0002-1284-8880
dc.identifier.orcid0000-0002-3790-0323
dc.identifier.orcid0000-0003-0207-2246
dc.identifier.orcid0000-0001-7620-9984
dc.identifier.pmid32561300
dc.identifier.scopus2-s2.0-85087213251
dc.identifier.scopusqualityQ1
dc.identifier.startpage1513
dc.identifier.urihttps://doi.org/10.1016/j.drudis.2020.06.006
dc.identifier.urihttps://hdl.handle.net/20.500.14854/11082
dc.identifier.volume25
dc.identifier.wosWOS:000564772600022
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofDrug Discovery Today
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20251020
dc.subjectCo-Delivery
dc.subjectControlled-Release
dc.subjectIn-Vitro
dc.subjectCancer
dc.subjectTherapy
dc.subjectSystems
dc.subjectDoxorubicin
dc.subjectPaclitaxel
dc.subjectNanotechnology
dc.subjectNanocarriers
dc.titleApplication of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents
dc.typeReview Article

Dosyalar